VESILUTE

Part of the Khavinson bioregulator family, this tripeptide targets the cardiovascular system with a specific focus on maintaining healthy blood vessel architecture. Researchers examine it primarily in the context of age-related vascular decline, where endothelial cells and arterial walls lose their structural integrity over time. The peptide represents an approach to cellular maintenance rather than acute therapeutic intervention.

The peptide works by binding to specific DNA sequences in vascular cells, acting as a genetic switch that can influence which proteins get produced. Think of it as a molecular instruction manual that tells blood vessel cells how to maintain themselves properly - it may help endothelial cells produce the right structural proteins and signaling molecules needed for vessel flexibility and strength. This gene regulation approach differs from traditional cardiovascular drugs that block or activate specific receptors.